Zepp Health Earnings Call Signals Profitable Turnaround Path

Zepp Health Corporation ((ZEPP)) has held its Q4 earnings call. Read on for the main highlights of the call.

Zepp Health’s latest earnings call struck an upbeat tone, with management emphasizing a clear operational turnaround built on rapid revenue growth and record margins. While executives acknowledged lingering losses, higher operating expenses, and some supply and cost headwinds, they framed these as manageable issues against a backdrop of accelerating demand and improving unit economics.

Strong Revenue Rebound Across 2025

Zepp Health reported full‑year 2025 revenue of $259 million, up 41.8% from $183 million a year earlier, underscoring a strong recovery in its core wearables business. Fourth‑quarter revenue of $85.2 million grew 43% year over year and landed at the high end of guidance, reinforcing the view that growth is not a one‑off.

Amazfit Brand Fuels Growth Engine

The Amazfit brand remained the growth engine, with full‑year branded product revenue climbing 51% year over year as the portfolio gained share across markets. In Q4, Amazfit sales rose 45.4% year over year and 12.4% sequentially, reflecting healthy demand in both entry‑level and premium segments.

Margins Hit Record Highs on Premium Mix

Profit quality improved alongside growth, with Q4 gross margin reaching a record roughly 40.4%, up about 3.6 percentage points versus the prior‑year quarter and 2.2 points versus Q3 2025. For the full year, gross margin was 38.3%, helped by a deliberate shift to higher‑priced devices and disciplined pricing even during promotional periods.

Losses Narrow but Profitability Still Elusive

Adjusted net losses narrowed meaningfully, signaling better operating leverage even as the company invests for growth. The Q4 adjusted net loss shrank to $6.4 million from $22.5 million a year ago, and full‑year adjusted net loss improved to $31.5 million versus $56.7 million in 2024.

Premiumization Strategy Gains Traction

Zepp Health’s premiumization push was visible in its product slate, which now spans from affordable devices to high‑end models such as the T‑Rex Ultra 2 at about $550. New launches like Active MAX, Active 3 Premium around $169, and T‑Rex 3 Pro helped lift average selling prices and tilt the mix toward higher‑margin SKUs.

Ecosystem Investments Deepen Brand Moat

Beyond hardware, the company is leaning into its ecosystem via Zepp OS upgrades and health features such as BioCharge and Zepp Coach AI to boost engagement and stickiness. Partnerships with elite athletes and integration with events like HYROX are designed to add performance credibility while driving organic brand exposure in key fitness communities.

Stronger Cash Generation and Leaner Inventory

The balance sheet showed continued healing, with cash and cash equivalents at $113 million as of year‑end, slightly above the prior‑year level. Inventory fell to $72.8 million from $87.7 million in Q3 2025, while operating cash flow remained positive and the company has retired a cumulative $58 million of debt since 2023.

Guidance Signals Confidence in 2026 Trajectory

For Q1 2026, Zepp Health guided revenue to $50 million to $55 million, implying robust year‑over‑year growth between 30% and 43% supported by new launches and a richer premium mix. Management expects margins to continue expanding as one‑off costs subside, operating expenses trend down relative to sales, liquidity remains solid, and a share‑repurchase plan and ongoing R&D and marketing spend underpin the growth strategy.

Zepp Health’s call painted a picture of a company transitioning from repair to expansion, with strong top‑line growth and record margins now offsetting earlier setbacks. While the business is not yet profitable and still faces cost and supply challenges, management’s guidance and capital allocation plans suggest a constructive setup for investors watching its 2026 execution.